Sambria Pharmaceuticals
About Sambria Pharmaceuticals
Sambria Pharmaceuticals is focused on patient comfort and healing!
Formed in April, 2012, Sambria Pharmaceuticals is the developer and marketer of topically applied therapeutics combined with the Company’s proprietary formulation that includes both skin conditioning agents and its absorption enhancement technology. The Company’s launch product, NeuroMed7®, is a topical anesthetic with rapid onset properties combining lidocaine HCl 4% with its proprietary blend. This launch product is currently being supplied to and used in a variety of medical specialties and industries.
Currently in Sambria Pharmaceuticals’ pipeline is a variety of other therapeutics combined with its formulation that are focused on patient post-procedural aftercare. The Company is also investigating the delivery of small molecule biologic therapeutics for a variety of medical applications.
Formed in April, 2012, Sambria Pharmaceuticals is the developer and marketer of topically applied therapeutics combined with the Company’s proprietary formulation that includes both skin conditioning agents and its absorption enhancement technology. The Company’s launch product, NeuroMed7®, is a topical anesthetic with rapid onset properties combining lidocaine HCl 4% with its proprietary blend. This launch product is currently being supplied to and used in a variety of medical specialties and industries.
Currently in Sambria Pharmaceuticals’ pipeline is a variety of other therapeutics combined with its formulation that are focused on patient post-procedural aftercare. The Company is also investigating the delivery of small molecule biologic therapeutics for a variety of medical applications.